vs
Avantor, Inc.（AVTR）与帕可Bio（PACB）财务数据对比。点击上方公司名可切换其他公司
Avantor, Inc.的季度营收约是帕可Bio的37.3倍（$1.7B vs $44.6M）。Avantor, Inc.净利率更高（3.1% vs -90.4%，领先93.6%）。帕可Bio同比增速更快（13.8% vs -1.4%）。Avantor, Inc.自由现金流更多（$117.2M vs $-19.9M）。过去两年帕可Bio的营收复合增速更高（7.3% vs -0.5%）
Avantor是一家总部位于美国宾夕法尼亚州拉德诺的生物技术、化工及制药领域企业，前身为1904年成立的J.T. Baker，2010年正式更名，2019年在纽约证券交易所挂牌上市，股票代码为AVTR，为全球生命科学、医疗健康等行业客户提供核心产品与服务。
太平洋生物科学（加利福尼亚）公司是2004年成立的美国生物技术企业，专注于研发生产基因测序相关设备，还可实现新型实时生物观测。公司拥有两大核心测序平台：基于零模波导特性的单分子实时测序平台（SMRT），以及采用天然核苷酸、无损伤掺入完成DNA结合与延伸的结合测序技术（SBB）平台。
AVTR vs PACB — 直观对比
营收规模更大
AVTR
是对方的37.3倍
$44.6M
营收增速更快
PACB
高出15.2%
-1.4%
净利率更高
AVTR
高出93.6%
-90.4%
自由现金流更多
AVTR
多$137.1M
$-19.9M
两年增速更快
PACB
近两年复合增速
-0.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.7B | $44.6M |
| 净利润 | $52.4M | $-40.4M |
| 毛利率 | 31.5% | 37.1% |
| 营业利润率 | 7.6% | -92.3% |
| 净利率 | 3.1% | -90.4% |
| 营收同比 | -1.4% | 13.8% |
| 净利润同比 | -89.5% | -1802.7% |
| 每股收益（稀释后） | $0.08 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVTRPACB
| Q4 25 | $1.7B | $44.6M | ||
| Q3 25 | $1.6B | $38.4M | ||
| Q2 25 | $1.7B | $39.8M | ||
| Q1 25 | $1.6B | $37.2M | ||
| Q4 24 | $1.7B | $39.2M | ||
| Q3 24 | $1.7B | $40.0M | ||
| Q2 24 | $1.7B | $36.0M | ||
| Q1 24 | $1.7B | $38.8M |
净利润AVTRPACB
| Q4 25 | $52.4M | $-40.4M | ||
| Q3 25 | $-711.8M | $-38.0M | ||
| Q2 25 | $64.7M | $-41.9M | ||
| Q1 25 | $64.5M | $-426.1M | ||
| Q4 24 | $500.4M | $2.4M | ||
| Q3 24 | $57.8M | $-60.7M | ||
| Q2 24 | $92.9M | $-173.3M | ||
| Q1 24 | $60.4M | $-78.2M |
毛利率AVTRPACB
| Q4 25 | 31.5% | 37.1% | ||
| Q3 25 | 32.4% | 41.4% | ||
| Q2 25 | 32.9% | 36.9% | ||
| Q1 25 | 33.8% | -3.7% | ||
| Q4 24 | 33.4% | 25.6% | ||
| Q3 24 | 32.9% | 25.0% | ||
| Q2 24 | 34.1% | 16.5% | ||
| Q1 24 | 34.0% | 29.1% |
营业利润率AVTRPACB
| Q4 25 | 7.6% | -92.3% | ||
| Q3 25 | -40.0% | -101.1% | ||
| Q2 25 | 7.7% | -112.8% | ||
| Q1 25 | 9.3% | -1154.5% | ||
| Q4 24 | 37.8% | -390.1% | ||
| Q3 24 | 7.3% | -160.3% | ||
| Q2 24 | 10.3% | -488.3% | ||
| Q1 24 | 8.7% | -209.6% |
净利率AVTRPACB
| Q4 25 | 3.1% | -90.4% | ||
| Q3 25 | -43.8% | -98.9% | ||
| Q2 25 | 3.8% | -105.4% | ||
| Q1 25 | 4.1% | -1146.8% | ||
| Q4 24 | 29.7% | 6.0% | ||
| Q3 24 | 3.4% | -151.9% | ||
| Q2 24 | 5.5% | -481.3% | ||
| Q1 24 | 3.6% | -201.4% |
每股收益（稀释后）AVTRPACB
| Q4 25 | $0.08 | $-0.11 | ||
| Q3 25 | $-1.04 | $-0.13 | ||
| Q2 25 | $0.09 | $-0.14 | ||
| Q1 25 | $0.09 | $-1.44 | ||
| Q4 24 | $0.73 | $-0.44 | ||
| Q3 24 | $0.08 | $-0.22 | ||
| Q2 24 | $0.14 | $-0.64 | ||
| Q1 24 | $0.09 | $-0.29 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $365.4M | $279.5M |
| 总债务越低越好 | $3.9B | — |
| 股东权益账面价值 | $5.6B | $5.3M |
| 总资产 | $11.8B | $784.1M |
| 负债/权益比越低杠杆越低 | 0.71× | — |
8季度趋势，按日历期对齐
现金及短期投资AVTRPACB
| Q4 25 | $365.4M | $279.5M | ||
| Q3 25 | $251.9M | $298.7M | ||
| Q2 25 | $449.4M | $314.7M | ||
| Q1 25 | $315.7M | $343.1M | ||
| Q4 24 | $261.9M | $389.9M | ||
| Q3 24 | $285.3M | $471.1M | ||
| Q2 24 | $272.6M | $509.8M | ||
| Q1 24 | $234.9M | $561.9M |
总债务AVTRPACB
| Q4 25 | $3.9B | — | ||
| Q3 25 | $3.9B | — | ||
| Q2 25 | $4.2B | — | ||
| Q1 25 | $4.1B | — | ||
| Q4 24 | $4.1B | — | ||
| Q3 24 | $4.9B | — | ||
| Q2 24 | $5.1B | — | ||
| Q1 24 | $5.3B | — |
股东权益AVTRPACB
| Q4 25 | $5.6B | $5.3M | ||
| Q3 25 | $5.6B | $36.1M | ||
| Q2 25 | $6.3B | $61.5M | ||
| Q1 25 | $6.1B | $91.6M | ||
| Q4 24 | $6.0B | $506.6M | ||
| Q3 24 | $5.6B | $453.1M | ||
| Q2 24 | $5.4B | $492.7M | ||
| Q1 24 | $5.3B | $649.0M |
总资产AVTRPACB
| Q4 25 | $11.8B | $784.1M | ||
| Q3 25 | $11.7B | $803.2M | ||
| Q2 25 | $12.8B | $825.5M | ||
| Q1 25 | $12.3B | $860.8M | ||
| Q4 24 | $12.1B | $1.3B | ||
| Q3 24 | $12.8B | $1.5B | ||
| Q2 24 | $12.7B | $1.5B | ||
| Q1 24 | $12.8B | $1.7B |
负债/权益比AVTRPACB
| Q4 25 | 0.71× | — | ||
| Q3 25 | 0.69× | — | ||
| Q2 25 | 0.67× | — | ||
| Q1 25 | 0.67× | — | ||
| Q4 24 | 0.68× | — | ||
| Q3 24 | 0.89× | — | ||
| Q2 24 | 0.94× | — | ||
| Q1 24 | 1.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $152.7M | $-19.1M |
| 自由现金流经营现金流 - 资本支出 | $117.2M | $-19.9M |
| 自由现金流率自由现金流/营收 | 7.0% | -44.6% |
| 资本支出强度资本支出/营收 | 2.1% | 1.9% |
| 现金转化率经营现金流/净利润 | 2.91× | — |
| 过去12个月自由现金流最近4个季度 | $495.0M | $-114.1M |
8季度趋势，按日历期对齐
经营现金流AVTRPACB
| Q4 25 | $152.7M | $-19.1M | ||
| Q3 25 | $207.4M | $-18.7M | ||
| Q2 25 | $154.4M | $-29.4M | ||
| Q1 25 | $109.3M | $-44.1M | ||
| Q4 24 | $173.3M | $-30.6M | ||
| Q3 24 | $244.8M | $-45.5M | ||
| Q2 24 | $281.1M | $-54.3M | ||
| Q1 24 | $141.6M | $-75.7M |
自由现金流AVTRPACB
| Q4 25 | $117.2M | $-19.9M | ||
| Q3 25 | $171.7M | $-18.8M | ||
| Q2 25 | $124.8M | $-29.9M | ||
| Q1 25 | $81.3M | $-45.4M | ||
| Q4 24 | $145.8M | $-32.3M | ||
| Q3 24 | $204.0M | $-46.3M | ||
| Q2 24 | $235.3M | $-55.7M | ||
| Q1 24 | $106.9M | $-79.6M |
自由现金流率AVTRPACB
| Q4 25 | 7.0% | -44.6% | ||
| Q3 25 | 10.6% | -48.9% | ||
| Q2 25 | 7.4% | -75.3% | ||
| Q1 25 | 5.1% | -122.3% | ||
| Q4 24 | 8.6% | -82.3% | ||
| Q3 24 | 11.9% | -115.7% | ||
| Q2 24 | 13.8% | -154.8% | ||
| Q1 24 | 6.4% | -205.0% |
资本支出强度AVTRPACB
| Q4 25 | 2.1% | 1.9% | ||
| Q3 25 | 2.2% | 0.2% | ||
| Q2 25 | 1.8% | 1.4% | ||
| Q1 25 | 1.8% | 3.7% | ||
| Q4 24 | 1.6% | 4.1% | ||
| Q3 24 | 2.4% | 2.0% | ||
| Q2 24 | 2.7% | 4.1% | ||
| Q1 24 | 2.1% | 10.0% |
现金转化率AVTRPACB
| Q4 25 | 2.91× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 2.39× | — | ||
| Q1 25 | 1.69× | — | ||
| Q4 24 | 0.35× | -12.93× | ||
| Q3 24 | 4.24× | — | ||
| Q2 24 | 3.03× | — | ||
| Q1 24 | 2.34× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVTR
| Laboratory Solutions Segment | $1.1B | 67% |
| Bioscience Production Segment | $547.5M | 33% |
PACB
| Products | $39.0M | 87% |
| Service And Other | $5.7M | 13% |
